
|Articles|September 27, 2014
- Head and Neck Cancers (Issue 2)
- Volume 2
- Issue 1
Sequencing Sorafenib and Lenvatinib in Thyroid Cancer
Author(s)Marcia S. Brose, MD, PhD, FASCO
Marcia S. Brose, MD, PhD, discusses using both sorafenib and lenvatinib as treatment options for thyroid cancer.
Advertisement
Articles in this issue
over 11 years ago
Treatment Update: Unresectable Medullary Thyroid Cancerover 11 years ago
The Side Effects of Lenvatinibover 11 years ago
Immune Checkpoint Inhibitors for Head and Neck Cancersover 11 years ago
Battling the Immunosuppressive Nature of Head and Neck CancerAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















